Pirfenidone inhibits macrophage infiltration in 5/6 nephrectomized rats (Q44328029)

2 December 2017

Pirfenidone inhibits macrophage infiltration in 5/6 nephrectomized rats (English)

1 reference

2 December 2017

1 reference

Jun-Feng Chen

1

1 reference

2 December 2017

Hai-Feng Ni

2

1 reference

2 December 2017

Ming-Ming Pan

3

1 reference

2 December 2017

Hong Liu

4

1 reference

2 December 2017

Min Xu

5

1 reference

2 December 2017

Ming-Hui Zhang

6

1 reference

2 December 2017

Bi-Cheng Liu

7

1 reference

2 December 2017

14 November 2012

1 reference

American Journal of Physiology - Renal Physiology

2 December 2017

1 reference

2 December 2017

304

1 reference

2 December 2017

F676-85

1 reference

2 December 2017

6

1 reference

Renal microenvironments and macrophage phenotypes determine progression or resolution of renal inflammation and fibrosis.

2 December 2017

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00507.2012

A pilot study in patients with established advanced liver fibrosis using pirfenidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00507.2012

Macrophage phenotype as a determinant of biologic scaffold remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00507.2012

The phenotype of murine wound macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00507.2012

Repertoire of microglial and macrophage responses after spinal cord injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00507.2012

Effect of allopurinol in chronic kidney disease progression and cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00507.2012

c-fms blockade reverses glomerular macrophage infiltration and halts development of crescentic anti-GBM glomerulonephritis in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00507.2012

Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00507.2012

Differential regulation of nitric oxide synthase-2 and arginase-1 by type 1/type 2 cytokines in vivo: granulomatous pathology is shaped by the pattern of L-arginine metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00507.2012

Quantitative morphometry of lupus nephritis: the significance of collagen, tubular space, and inflammatory infiltrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00507.2012

Anti-inflammatory effect of pirfenidone in the bleomycin-hamster model of lung inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00507.2012

Pirfenidone and candesartan ameliorate morphological damage in mild chronic anti-GBM nephritis in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00507.2012

Monocytes induce proximal tubular epithelial-mesenchymal transition through NF-kappa B dependent upregulation of ICAM-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00507.2012

Pirfenidone inhibits inflammatory responses and ameliorates allograft injury in a rat lung transplant model

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00507.2012

Apoptotic cells and innate immune stimuli combine to regulate macrophage cytokine secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00507.2012

The Pin 1 inhibitor juglone attenuates kidney fibrogenesis via Pin 1-independent mechanisms in the unilateral ureteral occlusion model

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00507.2012

Macrophages in skin injury and repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00507.2012

The chemokine system in diverse forms of macrophage activation and polarization

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00507.2012

Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00507.2012

Macrophage activation and polarization

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00507.2012

Pirfenidone inhibits obliterative airway disease in a murine heterotopic tracheal transplant model

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00507.2012

Monitoring of inflammation in patients on dialysis: forewarned is forearmed

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00507.2012

The many faces of macrophage activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00507.2012

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00507.2012

Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00507.2012

Pirfenidone is renoprotective in diabetic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00507.2012

Increased oxidative stress and apoptosis in acute puromycin aminonucleoside nephrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00507.2012

Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00507.2012

Pirfenidone for diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00507.2012

Renoprotective properties of pirfenidone in subtotally nephrectomized rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00507.2012

Macrophages and renal fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00507.2012

Targeting the recruitment of monocytes and macrophages in renal disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00507.2012

Pirfenidone inhibits T-cell activation, proliferation, cytokine and chemokine production, and host alloresponses

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00507.2012

A double-blind, randomized, controlled study of oral pirfenidone for treatment of secondary progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00507.2012

Integrating mechanisms of pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00507.2012

Pirfenidone Slows Renal Function Decline in Patients with Focal Segmental Glomerulosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00507.2012

10.1152/AJPRENAL.00507.2012

21 January 2018

Identifiers

DOI

1 reference

2 December 2017

1 reference